Velos, Inc. hosted a constellation of academic medical centers, research institutions, investigative leaders and industry partners at its annual meeting in San Francisco. Velos customers from throughout the world gathered to discuss a variety of initiatives and to hear speakers from UCLA, SUNY Stony Brook, Kansas University, University of Michigan, Columbia University, and the University of Texas Southwestern and M.D. Anderson Cancer Center. Presenters shared their achievements using the Velos flagship product, Velos eResearch. They addressed other topics such as strategies to facilitate better data standards for medical research."We're delighted to have such a high quality group of professionals participate in this year's gathering," said John S. McIlwain, President and CEO of Velos. "We are all celebrating a year of accomplishments. We believe our growing customer base has the capability to help move the entire clinical research industry forward. It's gratifying to think that Velos can contribute with its systems for medical research."This year's meeting was highlighted by customer enthusiasm and eagerness to collaborate in adopting state-of-the-art clinical research system infrastructure. The Velos eResearch system allows customers to internally and collaboratively manage thousands of clinical trials. Such themes as collaboration, multi-site research network management, service-oriented architecture, Web Services, outcomes measurement, patient self-reporting, and financial management were discussed throughout the two-day session. Attendees learned about developments at Velos. These include:Version 8.8 of Velos eResearch is released. Delivered closely on the heels of Velos eResearch 8.7, Velos eResearch 8.8 addresses customer needs and preferences in Electronic Data Capture. Velos 8.8 delivers a faster, more robust functionality and has a fuller set of features and benefits in Financial Management. Other highlights include: Connection Proofing; Forms and Dashboards; Closer Integration Between Calendars, Budgets and Milestones; Advanced Specimen Management; Enhanced Budget Display; Increased Efficiency in Milestone Creation; and Patient and Form Modifications. Velos eResearch eXpress is bringing new economies and benefits to support individual studies and departments within research institutions. Smaller research sites and biotechnology companies throughout the U.S. and internationally can access Velos eResearch eXpress when needed, without up front capital expenditure. Representative customers include: clinical trials offices that might not have budgets for larger enterprise rollouts; individual investigators; biotechnology companies; SMOs; and smaller CROs. Research programs within the international arena including Cancer Trials Australia (CTA). CTA will use Velos eResearch to collaborate across their 13-hospital research network. Additionally South Korea deployed Velos eResearch in 2007 in an initiative to allow seamless clinical trial collaboration and information sharing among all South Korean cancer centers.Velos eResearch customers receive over 50 percent of the NIH extramural medical research funding to the 100 largest such recipients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
2 Commerce Drive
Cranbury, NJ 08512